Siok-Keen Tey

Siok-Keen Tey

Auto-generated profile, based on publicly available information

Siok-Keen Tey

QIMR Berghofer Medical Research Institute, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ASAntonio Di Stasi
Antonio Di Stasi
STSiok-Keen Tey
Siok-Keen Tey
GDGianpietro Dotti
Gianpietro Dotti
YFYuriko Fujita
Yuriko Fujita
AKAlana Kennedy-Nasser
Alana Kennedy-Nasser
MBMalcolm K. Brenner
Malcolm K. Brenner
Cellular therapies could play a role in cancer treatment and regenerative medicine if it were possible to quickly eliminate the infused cells in case of adverse events. We devised an inducible T-cell safety switch that is based on the fusion of human caspase 9 to a modified human FK-binding protein, allowing conditional dimerization. When exposed to a synthetic dimerizing drug, the inducible caspase 9 (iCasp9) becomes activated and leads to the rapid death of cells expressing this construct. We tested the activity of our safety switch by introducing the gene into donor T cells given to enhance immune reconstitution in recipients of haploidentical stem-cell transplants. Patients received AP1903, an otherwise bioinert small-molecule dimerizing drug, if graft-versus-host disease (GVHD) developed. We measured the effects of AP1903 on GVHD and on the function and persistence of the cells containing the iCasp9 safety switch. Five patients between the ages of 3 and 17 years who had undergone stem-cell transplantation for relapsed acute leukemia were treated with the genetically modified T cells. The cells were detected in peripheral blood from all five patients and increased in number over time, despite their constitutive transgene expression. A single dose of dimerizing drug, given to four patients in whom GVHD developed, eliminated more than 90% of the modified T cells within 30 minutes after administration and ended the GVHD without recurrence. The iCasp9 cell-suicide system may increase the safety of cellular therapies and expand their clinical applications. (Funded by the National Heart, Lung, and Blood Institute and the National Cancer Institute; ClinicalTrials.gov number, NCT00710892.)

24 August 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
SNSusanna S Ng
Susanna S Ng
FRFabian De Labastida Rivera
Fabian De Labastida Rivera
JYJuming Yan
Juming Yan
DCDillon Corvino
Dillon Corvino
IDIndrajit Das
Indrajit Das
CEChristian R. Engwerda
Christian R. Engwerda

1 December 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
GKGlen A Kennedy
Glen A Kennedy
AVAntiopi Varelias
Antiopi Varelias
SVSlavica Vuckovic
Slavica Vuckovic
LTLaetitia Le Texier
Laetitia Le Texier
KGKate H Gartlan
Kate H Gartlan
GHGeoffrey R Hill
Geoffrey R Hill

1 August 2007 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
STSiok-Keen Tey
Siok-Keen Tey
GDGianpietro Dotti
Gianpietro Dotti
CRCliona M. Rooney
Cliona M. Rooney
HHHelen E. Heslop
Helen E. Heslop
MBMalcolm K. Brenner
Malcolm K. Brenner
Addback of donor T cells following T cell-depleted stem cell transplantation (SCT) can accelerate immune reconstitution and be effective against relapsed malignancy. After haploidentical SCT, a high risk of graft-versus-host disease (GVHD) essentially precludes this option, unless the T cells are first depleted of alloreactive precursor cells. Even then, the risks of severe GVHD remain significant. To increase the safety of the approach and thereby permit administration of larger T cell doses, we used a suicide gene, inducible caspase 9 (iCasp9), to transduce allodepleted T cells, permitting their destruction should administration have adverse effects. We made a retroviral vector encoding iCasp9 and a selectable marker (truncated CD19). Even after allodepletion (using anti-CD25 immunotoxin), donor T cells could be efficiently transduced, expanded, and subsequently enriched by CD19 immunomagnetic selection to >90% purity. These engineered cells retained antiviral specificity and functionality, and contained a subset with regulatory phenotype and function. Activating iCasp9 with a small-molecule dimerizer rapidly produced >90% apoptosis. Although transgene expression was downregulated in quiescent T cells, iCasp9 remained an efficient suicide gene, as expression was rapidly upregulated in activated (alloreactive) T cells. We have demonstrated the clinical feasibility of this approach after haploidentical transplantation by scaling up production using clinical grade materials.

19 June 2014 in Blood
Verified
Journal Article
Open access
PDF file
XZXiaoou Zhou
Xiaoou Zhou
ASAntonio Di Stasi
Antonio Di Stasi
STSiok-Keen Tey
Siok-Keen Tey
RKRobert A. Krance
Robert A. Krance
CMCaridad Martinez
Caridad Martinez
GDGianpietro Dotti
Gianpietro Dotti
Key Points: Allodepleted-T-cells containing the iC9 safety gene persist long-term in vivo, promote immune recovery, and protect against infections. GvHD caused by iC9-T cells can be permanently controlled by a single administration of AP1903 without abrogating immune reconstitution.

21 April 2017 in Science Immunology
Verified
Journal Article
Closed access
PDF file
Ping ZhangPing Zhang
Ping Zhang
Jason S. LeeJason S. Lee
Jason S. Lee
KGKate H. Gartlan
Kate H. Gartlan
ISIona S. Schuster
Iona S. Schuster
ICIain Comerford
Iain Comerford
GHGeoffrey R. Hill
Geoffrey R. Hill
T R 1 cells are the major regulatory population generated after allogeneic bone marrow transplantation.